the realities of health care decision-making · welcome to the 2014 cadth symposium, the tenth...

The Realities of Health Care Decision-Making:EVIDENCE, VALUES, AND COLLABORATION

2014 CADTH Symposium | April 6 to 8 | Hilton Lac-Leamy | Gatineau, Quebec

Welcome to the 2014 CADTH Symposium, the tenth pan-Canadian forum organized by the Canadian Agency for Drugs and Technologies in Health for producers and users of evidence-based information on drugs and other health technologies in Canada. As always, the CADTH Symposium is an opportunity for productive dialogue among the various sectors with an interest in how evidence is used to support informed decisions about drugs and other health technologies. This year, it is also an opportunity to celebrate an important milestone in CADTH’s history – CADTH’s 25th anniversary. For a quarter of a century, CADTH has proudly contributed to the effectiveness, quality and sustainability of health care in Canada. We’ve changed and grown throughout our history, adding new programs, increasing our expertise, and improving our methodology and processes in order to continually meet the changing needs of our customers – health care decision-makers. I’d like to thank everyone who has contributed to CADTH’s development, growth and success over the years – the staff, Board and committee members, clinical and economic experts, patient groups, our partners, collaborators and stakeholders, our funders and especially the decision-makers who use CADTH’s products and services to keep our health system strong. The theme of this year’s Symposium is The Realities of Health Care Decision-Making: Evidence, Values, and Collaboration. Through 3 plenary sessions, 22 panel discussions, 9 oral sessions, 13 workshops and more than 40 scientific posters, you’ll have an opportunity to get an inside look at some of the tools, methods and collaborative approaches that are successfully enhancing decision-making, reducing uncertainty, improving health outcomes and increasing the value and sustainability of health care in Canada and around the world. There are also a number of informal networking opportunities at the Symposium, including the Welcome Reception and Scientific Poster Exhibition on Sunday evening and the Awards Luncheon on Tuesday – where you’ll have a chance to celebrate some of the founders and earliest champions of health technology assessment in Canada. I hope that you find the discussions and networking productive and rewarding.

Dr. Brian O’Rourke, President and CEO, CADTH

THANK YOUTO OUR SPONSORS

We would also like to acknowledge the support of our funders. CADTH’s activities, programs, and services, including the CADTH Symposium, are made possible through financial

contributions from Health Canada and the governments of:

We gratefully acknowledge the contribution of our sponsors to the success of the 2014 CADTH Symposium.

This event could not continue to grow and improve without you!

GOLD SPONSORS

SILVER SPONSORS

AlbertaBritish ColumbiaPrince Edward IslandManitobaNew BrunswickNova Scotia

NunavutOntarioSaskatchewanNewfoundland and LabradorNorthwest TerritoriesYukon

The Realities of Health Care Decision-Making: EVIDENCE, VALUES, AND COLLABORATION PROGRAM AT A GLANCE

1 | Page

Program at a Glance SUNDAY, APRIL 6, 2014

Time Event Speakers Location

0800 – 1900 Registration Desk Open

0800 – 0900 Morning Workshop Registration

0900 – 1200 Workshop AM-1 Critical Appraisal 101 for Non-Researchers – Part 1: Understanding RCTs and Observational Studies

Brendalynn Ens Dr. Gabrielle

Zimmermann Chris Kamel

Morrice

Workshop AM-2 Applying Value Frameworks to HTA and Decision-Making

Dr. Craig Mitton Dr. François Dionne Dr. Larry Lynd Dr. Jennifer Gibson Erik Lockhart

Beethoven

Workshop AM-3 Navigating the Maze: Finding Regulatory Information on Pharmaceuticals

Melissa Severn Laura Johnson René-Pierre Charron Caitlyn Ford

Julien

Workshop AM-4 Innovative Approaches to Strengthening Patient Input Submissions

Barbara Santosuosso Dr. Ahmed Bayoumi

Walker

Workshop AM-5 Utilities: What Are They? Why Do They Matter?

Dr. Julie Blouin Dr. Dan Cooper

Suzor-Côté

Workshop AM-6 Critical Appraisal of Network Meta-Analysis for Health Technology Assessments

Dr. Kristian Thorlund Dr. Brian Hutton

Kreighoff

Workshop AM-7 Qualitative Research Methods and HTA: An Unlikely Marriage?

Dr. Gail MacKean

Gagnon

Workshop AM-8 Opportunity (Cost) Knocks! Getting the Most Out of HTA Resources

Chantelle Garritty Ken Bond Dr. Stephen Bornstein Dr. Nina Buscemi Dr. Ava John-Baptiste Dr. Don Juzwishin Mike Paulden Arianna Waye

Salon du Jardin

1200 – 1300 Lunch can be purchased at Snack Bar located on Ballroom Level Afternoon Workshop Registration

Abstracts are available on the USB stick in the delegate kit, online at

www.cadth.ca/symposium2014, and through the CADTH Symposium App.


2 | Page

SUNDAY, APRIL 6, 2014 (cont’d)


1300 – 1600 Workshop PM-1 Critical Appraisal 101 for Non-Researchers – Part 2: Systematic Reviews and Clinical Practice Guidelines

Brendalynn Ens Dr. Gabrielle

Zimmermann Chris Kamel

Morrice

Workshop PM-2 Introduction to the Joanna Briggs Institute Methodology

Amanda Ross-White Dr. Margaret Harrison Dr. Christina Godfrey

Gagnon

Workshop PM-3 Incorporating Patient-Reported Outcome Measures in Reimbursement Decision-Making: Measuring and Valuing Health Using the EQ-5D

Dr. Feng Xie Dr. Simon Pickard Dr. Paul Kind

Suzor-Côté

Workshop PM-4 An Interactive Workshop on Network Meta-Analysis: From Idea Inception to Policy Decision

Dr. George Wells Chris Cameron Shannon Kelly Dr. Doug Coyle

Salon du Jardin

Workshop PM-5 Knowledge Mobilization and Social Media: What You Need to Know

Allan McDougall Dr. Janice Mann Andrea Tiwari Scott Gavura Pat Rich

Kreighoff

1700 – 1900 Welcome Reception and Scientific Poster Exhibition Ballroom Foyer

Abstracts are available on the USB stick in the delegate kit, online at

www.cadth.ca/symposium2014, and through the CADTH Symposium App.


3 | Page

MONDAY, APRIL 7



0745 – 0845 Breakfast Ballroom Foyer

0845 – 0915 Official Opening Dr. Brian O’Rourke The Honourable

Fred Horne

Ballroom

0915 – 1030 Opening Plenary Session Why On Earth Should We Fund That?

Brent Fraser Dr. Zayna Khayat Dr. François Meyer Mark Schaan Dr. Tammy Clifford

Ballroom

1030 – 1100 Refreshment Break Ballroom Foyer

1100 – 1230 Concurrent Session A1 Values

Dr. Nick Bansback Shannon Gibson Elizabeth Wilcox

Kreighoff

Concurrent Session A2 Formulary Management

Gary Warwick Jennifer Tung Janice Ma Mike Paulden

Salon du Jardin

Concurrent Session A3 Concept of Value in the Canadian Drug Reimbursement Environment

Sherry O’Quinn Dr. Jeffrey Hoch Carole McMahon Dr. Chander Sehgal Brent Fraser Jennifer Chan

Delfosse

Concurrent Session A4 Exploring the Tough Questions About Patient Input in Drug Appraisals

Graeme Fraser Mona Sabharwal Frank Gavin Annette Cyr Dr. Tom Noseworthy

Julien/Gagnon/Walker

Concurrent Session A5 HTA for Non-Drug Technologies: Current Initiatives Across Canada

Dr. Reiner Banken Dr. Nina Buscemi Sumeet Singh Trevor Richter Kevin Samra

Suzor-Côté

Concurrent Session A6 Use of Cost-Effectiveness in Reimbursement Decisions – Canadian Perspectives

Karen Lee Dr. Doug Coyle Dr. Ahmed Bayoumi Dr. Dan Cooper

Morrice

1230 – 1330 Lunch Ballroom

Abstracts are available on the USB stick in the delegate kit, online at www.cadth.ca/symposium2014, and through the CADTH Symposium App.


4 | Page

MONDAY, APRIL 7 (cont’d)


1330 – 1500 Concurrent Session B1 Resource Allocation

Neale Smith Dr. Zahava

Rosenberg-Yunger Laura Dowling

Kreighoff

Concurrent Session B2 Collaboration

Karen Lee Robert Tam Dr. Michael Cheng Dr. Gabrielle

Zimmermann Jeannette Smith

Salon du Jardin

Concurrent Session B3 Is a Health Economics Model With a Head-to-Head Study That Has a Comparator Which is Not the Standard of Care Better Than an Indirect Comparison?

Dr. Jeffrey Hoch Farah Jivraj Khamis Dr. George Wells Mike Innes Mona Sabharwal Christine Seager Dr. Stirling Bryan

Delfosse

Concurrent Session B4 The Development of a Canadian Top 10 List of New and Emerging Health Technologies

Prof. Ron Goeree Rosmin Esmail Dr. Davy Cheng Dr. Nina Buscemi Nelson Millar


Concurrent Session B5 High Impact Patient Input: How to Effectively Establish Patient Values

Ken Chan Dr. Jim Lavery Elaine MacPhail Victoria Thomas Carole McMahon

Suzor-Côté

Concurrent Session B6 Does It Make Sense to Expand An Evidence Synthesis of Randomized Trials With Observational Real World Data?

Dr. Kristian Thorlund Dr. Hongbo Yuan Dr. Brian Hutton

Morrice

Concurrent Session B7 Designing and Live Networking Technology Assessment and Intervention Modes (ETMI) in Quebec to Support Decision-Making

Dr. Reiner Banken Pierre Dagenais Denis A. Roy Sylvie St-Jacques

Ballroom (This session will be presented in French with English translation)




5 | Page

MONDAY, APRIL 7 (cont’d)


1530 – 1700 Concurrent Session C1 Evidence

Dr. Stéphane Bouchard

Dr. Anita Carrie Christine Lobè

Ballroom

Concurrent Session C2 Finding the Evidence

Amanda Hodgson Brendalynn Ens Dr. Deirdre DeJean Meredith Vanstone

Kreighoff

Concurrent Session C3 Early Engagement – “One Stop Shop”

Adrian Griffin Dr. Leeza Osipenko Dr. Indranil Bagchi Dr. Terri O’Grady Dr. François Meyer

Delfosse

Concurrent Session C4 Meeting NEED With SPEED: How Rapid Reviews are Changing the HTA/Evidence Landscape

Shannon Kelly Chris Cameron Sarah Bermingham Dr. Susan Myles Alexandra Chambers


Concurrent Session C5 Appropriateness of Care – The Choosing Wisely Campaign

Dr. Wendy Levinson Dr. Samuel Shortt Dr. Michelle

Mujoomdar Dr. Martin Reed

Morrice

Concurrent Session C6 Regulatory-HTA Perspectives and Interactions on Drug Review: Bridging the Gap

Matthew Brougham Dr. Robert Peterson Dr. Larry Liberti Barbara Sabourin Dr. Janet Martin

Suzor-Côté

1830 – 2230 SOCIAL EVENT – Meet us in the Market – An Evening of Epicurean Delights

Buses at front of hotel



6 | Page

TUESDAY, APRIL 8



0730 – 0830 Breakfast Ballroom

0830 – 0945 Plenary Session Big-Ticket Decisions in Canadian Hospitals

Katherine Chubbs Dr. Diane Francoeur Dr. Robert Halpenny Dr. Mike Tierney Dr. Rick Audas Dr. Tom Noseworthy

Ballroom


1015 – 1145 Concurrent Session D1 From Evidence to Policy

Philip Morehouse Daniel Grigat Janet Crain Dr. Janice Mann

Kreighoff

Concurrent Session D2 Health Technology Assessment of Biosimilars (SEBs): A Canadian Perspective

Angela Rocchi Dr. Jian Wang Dr. Chander Sehgal Steve Long Cheryl Koehn


Concurrent Session D3 Sending the Right Signals: How Can HTA Optimally Inform PLAs in the Context of pCPA?

Julia Brown Matthew Brougham Mona Sabharwal Carole Chambers Brad Alyward William Dempster

Delfosse

Concurrent Session D4 Disruptive Innovation in Health Care – Putting Theory Into Practice

Janet M. Davidson Eugene Patin Mark Schaan Dr. Jeffrey Hoch

Morrice

Concurrent Session D5 Generation and Use of HTA for Medical Devices: Issues, Challenges, Opportunities

Nicole Dekort Mike Tierney Dr. Les Levin Adrian Griffin Dr. Don Juzwishin Krista Stagliano

Suzor-Côté

Concurrent Session D6 Are Journals Still Relevant in the Electronic Age?

Dr. John Fletcher W. Anton Hart Dr. David Moher Dr. Michelle

Mujoomdar Dr. John O’Keefe Dr. Peter Tugwell

Salon du Jardin

1145 – 1300 Awards Luncheon Ballroom


7 | Page

TUESDAY, APRIL 8 (cont’d)


1300 – 1430 Concurrent Session E1 New Approaches

Dr. Doug Coyle Professor

Christopher McCabe Don Husereau Chris Cameron Eric Hellsten

Kreighoff

Concurrent Session E2 Values

Ken Bond Katherine Duthie Shirin Rizzardo Dr. Larry Lynd Tom Daniels

Salon du Jardin

Concurrent Session E3 Drugs for Rare Disorders: How Much Evidence Do We Really Need?

Wayne Critchley David Lee Eric Lun Dr. Jeffrey Hoch Ghislain Boudreau Dr. Chander Sehgal Barbara Shea

Delfosse

Concurrent Session E4 Is HTA More Similar Than Different Across the Atlantic? Comparison of Canada and Europe

Simone Warren Dr. Tammy Clifford Dr. Ansgar Hebborn Adrian Griffin Dr. François Meyer


Concurrent Session E5 Decision-Maker: Research Interfacing/The DSEN Canadian Experience

Dr. Robert Peterson Dr. George Wells Dr. Sasha Bernatsky Dr. Ingrid Sketris Dr. Pierre Ernst Susan Pierce

Suzor-Côté

Concurrent Session E6 Policy Confirmed. Now What?

Ronald Booth Phillip Morehouse Brendalynn Ens

Morrice


1500 – 1615 Closing Plenary Session Rethinking the QALY

Dr. Jennifer Gibson Dr. Ansgar Hebborn Professor

Christopher McCabe Don Husereau Dr. Stirling Bryan

Ballroom

1615 – 1630 Official Closing Dr. Brian O’Rourke Ballroom


The Realities of Health Care Decision-Making: EVIDENCE, VALUES, AND COLLABORATION SPECIAL EVENTS

8 | Page

WELCOME RECEPTION AND SCIENTIFIC POSTER EXHIBITION

Sunday, April 6 1700 – 1900

Ballroom Foyer

The Welcome Reception features scientific posters from across Canada and the opportunity to meet and talk with the authors about their work. A cash bar and light snacks will be available.

SOCIAL EVENT MEET US IN THE MARKET – AN EVENING OF EPICUREAN DELIGHTS

Monday, April 7 1830 – 2230

Meet at front door of hotel for bus pick-up

Buses will leave at

6:30 p.m. sharp

One of the best ways to learn about a city is to explore its neighbourhood food markets and discover local produce and dishes. We have planned a special gourmet walking tour, which is an ideal introduction to the National Capital Region’s vibrant food scene. Greet the bright lights and find the hidden treasures in one of Ottawa’s oldest neighbourhoods, the ByWard Market. This epicurean evening will take you to three different restaurants: one, for appetizers; one, for the main meal with wine; and the last, for a special dessert. Buses will transport you to and from the Hilton Lac-Leamy for this gastronomical event.

CADTH RECOGNITION AWARDS

Tuesday, April 8 1145 – 1315

Awards Luncheon

Ballroom

Join us in honouring the 2014 recipients of the CADTH Recognition Awards. Presentations will be made to winners of the Jill M. Sanders Award of Excellence in HTA, the Maurice McGregor Award, and the CADTH Anniversary Medals. The winners of our poster competition will also receive their awards at this luncheon. As this is a plated lunch, please arrive promptly.

The Realities of Health Care Decision-Making: EVIDENCE, VALUES, AND COLLABORATION PLENARY SESSIONS

9 | Page

April 7, 2014 0845 – 0915

OFFICIAL OPENING Dr. Brian O’Rourke, President and CEO of the Canadian Agency for Drugs and Technologies in Health, will welcome Symposium participants, describe some of the Symposium highlights and introduce The Honourable Fred Horne. Fred Horne was appointed as Alberta’s Minister of Health on May 8, 2012. He had served as Minister of Health and Wellness since October 2011. He also served as a member of the Cabinet Policy Committee on Public Health & Safety and the Treasury Board. And he was a member of the Standing Committee on Health. Previously, Mr. Horne served as Parliamentary Assistant to Health and Wellness. Previous committee involvement includes membership on the Select Special Chief Electoral Officer Search Committee and the Standing Committee on Legislative Offices, and Chair of the Standing Committee on Health. Prior to serving with the Legislative Assembly of Alberta, Mr. Horne worked as a health policy consultant for more than 25 years, serving various government bodies and regional health authorities in addition to the public, private, and not-for-profit sectors. Throughout his career Mr. Horne led initiatives to improve access and quality in Canadian public health care and has worked extensively with the Conference Board of Canada, the Alberta Government, and the Mayo Clinic. Mr. Horne holds a Master of Business Administration degree from Royal Roads University and a postgraduate certificate in dispute resolution from York University. Additionally, Mr. Horne is a former debater and coached Team Canada at the World Schools Debating Championships. For his continued contributions to the development of debate and speech programs Mr. Horne received the Queen Elizabeth II Golden Jubilee Medal in 2002.


10 | Page

PLENARY 1 April 7, 2014 0915 – 1030

Why On Earth Should We Fund That? Decision-makers are inundated with expensive new technologies, only some of which address their most pressing health care issues and many of which offer only marginal increases in clinical effectiveness. Why isn’t there a better alignment between the agendas of technology developers and policy-makers? What, if anything, can be done to bring these two worlds together? Brent Fraser is Director, Drug Program Services with the Ontario Public Drug Programs, Ontario Ministry of Health and Long-Term Care. Drug Program Services is responsible for managing all formulary listings and policies supporting the funding of these products including product listing negotiations, establishing a framework for funding drugs for rare diseases, increasing transparency in decision-making, and introducing patient input as part of the drug review process. Brent helped lead two broad stakeholder reviews of Ontario’s drug system resulting in reforms to the public and private sectors. These changes had an impact on pharmacy reimbursement and established payment for pharmacy professional services, reduced generic drug pricing, and revised the review and decision processes for new drugs. He is a representative on many national working groups for public drug policy and operations. Brent has a Bachelor of Science, Pharmacy from the University of Toronto, and a Master of Business Administration from York University, Ontario. Zayna Khayat, PhD, is the Senior Advisor, Health System Innovation at MaRS Discovery District, an innovation hub for Ontario and Canada, with a major focus on the health and life sciences sector. In this role, she is also the Director of the MaRS EXCITE program, a first-of-its kind, pre-market health technology evaluation program that collaboratively connects promising medical technologies with health system receptors that could most benefit from them. Prior to joining MaRS in February 2014, Dr. Khayat was a senior leader with the International Centre for Health Innovation at the Ivey Business School at Western University, where she currently is an adjunct faculty member. She is also an adjunct professor in the health strategy stream at the Rotman School of Management at the University of Toronto. From 2010 to 2012, Dr. Khayat was an associate partner with SECOR Consulting/KPMG Canada, where she worked closely with many agents in the Ontario health system and nationally, including CADTH, Health Quality Ontario, and Health Canada. Prior to joining


11 | Page

SECOR/KPMG, she was a Principal with the Toronto office of the Boston Consulting Group (BCG), a global strategy consulting firm. Dr. Khayat earned her PhD in biochemistry from the University of Toronto/Hospital for Sick Children, where she was a scholar of the Canadian Institutes of Health Research studying how insulin and exercise regulate blood glucose in the muscle. Dr. François Meyer is currently Advisor to the President of the French National Authority for Health (HAS, Haute Autorité de santé), with a particular focus on international affairs. He joined HAS in 2005, with the responsibility of setting up the HTA Division. In this role, he oversaw the grouping of the five major health technology domains (pharmaceuticals, medical devices, interventional and diagnostic procedures, and public health actions, and programs) under one roof, and led HAS’s expanding role of economic analysis in the field of HTA in France. Prior to joining HAS, Dr. Meyer worked for five years at the French Health Products Agency, initially as Deputy Director of the Regulatory Division and then as Director of the Drugs and Devices HTA Division. Prior to that, he worked for five years in the R&D Division of a pharmaceutical company. Dr. Meyer earned his MD degree from the L'Université de Montpellier Medical School in France. He served for more than 10 years in the teaching hospitals of Montpellier as a practising physician. Dr. Meyer is qualified in endocrinology and metabolic disorders, and internal medicine. Mark Schaan was appointed Director of Pharmaceutical Policy and Sector Intelligence, Life Sciences Industries Branch, Industry Canada in May 2011. From 2009 to 2011, Mark was a Senior Project Leader in the Automotive and Transportation Industries Branch of Industry Canada. He joined the branch to assist in the analysis of labour, pension and benefit issues in the restructuring of General Motors of Canada Limited, for which the team received a Public Service Award of Excellence for Exemplary Contribution under Extraordinary Circumstance. Prior to this, Mark was a Senior Policy Analyst at Human Resources and Skills Development Canada, where he assisted in analyses and policy development related to Canada’s Retirement Income System, for which his team received a Deputy Minister’s Award of Excellence. Throughout his time in the public service Mark has also been actively involved in the Recruitment of Policy Leaders program, an initiative aimed at bringing exceptional Canadian graduates into the public service


12 | Page

and enriching the government’s policy capacity. Mark served as coordinator of this initiative from 2007 to 2009. Mark earned his BA (Honours) from the University of Waterloo in Political Science with an honours option in Peace and Conflict Studies in 2002, where he studied as a Loran Scholar. Mark earned his MPhil in Comparative Social Policy, conferred in 2004, and his DPhil in Social Policy, conferred in 2010 from the University of Oxford, where he studied as a Rhodes Scholar. He has been awarded the Nathalie des Rosiers Audacity of Imagination Award, the Barnett Prize in Social Policy, and the University of Waterloo Young Alumni Award. MODERATOR: Dr. Tammy Clifford is the Vice-President, Strategic Initiatives, and Chief Scientist at the Canadian Agency for Drugs and Technologies in Health (CADTH). Her responsibilities include aligning the methods used in conducting CADTH's health technology assessments (HTAs) with best practices. She is also responsible for building capacity among producers and users of evidence-based assessments by providing education, training, and various brokering activities that facilitate the sharing of HTA work. Her portfolio also includes overseeing the Policy Forum, the Canadian Network for Environmental Scanning in Health (CNESH), the HTA Exchange, and horizon scanning. Dr. Clifford provides leadership to CADTH's scientific advice (early engagement) program, and to the agency's patient and citizen engagement activities. She has a keen interest in advancing evidence synthesis methods, and in promoting the value of transparency and collaboration. Dr. Clifford joined CADTH in 2005 as Director, Project Quality, and was appointed Vice-President of the Health Technology Assessment Directorate in 2008. She holds faculty appointments in Pediatrics, and in Epidemiology and Community Medicine, at the University of Ottawa. Dr. Clifford received her PhD in Epidemiology and Biostatistics from the University of Western Ontario, and both her BSc and MSc from McGill University. She is actively engaged with a number of national and international entities including the Canadian Institutes of Health Research and Health Technology Assessment international (HTAi), and serves as a reviewer for The Lancet, JAMA Pediatrics, PLOS ONE, Health Policy, and the International Journal of Technology Assessment in Health Care.


13 | Page

PLENARY 2

April 8, 2014 0830 – 0945

Big Ticket Decisions in Canadian Hospitals From surgical robots to 3T MRIs, Canadian hospitals are using new health technologies to deliver sophisticated, advanced patient care. But non-drug technologies can be expensive, and evidence about their safety, efficacy, and cost-effectiveness is often limited. Decisions about new equipment are made in the context of changing demographics, growing demands from clinicians and patients for the state-of-the-art technologies, competing internal priorities, tight budgets, and ever-increasing public scrutiny. So, what factors influence how and when acquisition decisions are made? Does HTA inform procurement decisions — and if not, why not? You’ll hear a range of perspectives on the acquisition of medical devices, the challenges of disinvestment, opportunity costs, and the role of evidence and context in the decision-making process. Dr. Rick Audas is an Associate Professor within the Faculty of Medicine at Memorial University who teaches Health Economics, Research Methods, and Health Technology Assessment. He is particularly interested in the medical device industry, employment issues among health professionals, and diagnostic imaging. More generally, he is interested in measuring health outcomes and health service utilization and understanding how health care expenditures can be more efficiently utilized to improve population health. Previously, Dr. Audas has held appointments at Bangor University (UK), Manchester University (UK), University of Newcastle upon Tyne (UK), University of New Brunswick, and Otago University (NZ). Katherine Chubbs is a Registered Nurse by profession, and holds the title of Vice-President and Chief Nursing Officer at Eastern Health, the largest health authority in Newfoundland and Labrador. Katherine has worked in a wide variety of clinical settings in urban, rural, and remotes areas. She currently has executive responsibility for the Provincial Cancer Care Program, the medicine program, the surgery program, and research and knowledge translation. Katherine has a diploma and Bachelor’s degree in Nursing, a certificate in Northern Nursing, a Masters in Health Studies – Leadership, and is pursuing a doctoral degree in Business Administration. As well as being a Certified Health Executive and presently Chair of the Newfoundland and Labrador Chapter of the Canadian College of Health Leaders (CCHL), Katherine is also the President of the Academy of Canadian Executive Nurses.


14 | Page

Dr. Diane Francoeur was appointed President of the Federation of Medical Specialists of Quebec on March 20, 2014. She obtained her doctorate in medicine from the Université Laval in 1987, followed by specialized training in obstetrics and gynecology (1988-1992) at the University of Montreal and additional postgraduate training in pediatric and adolescent gynecology (1992-1993) at the University of Louisville in Kentucky. She currently holds the position of Clinical Associate Professor in the Department of Obstetrics and Gynecology at the University of Montreal. Dr. Francoeur is also a member of the Association of Obstetricians and Gynecologists of Quebec (AOGQ), the North American Society for Pediatric and Adolescent Gynecology (NASPAG), and the Society of Obstetricians and Gynaecologists of Canada (SOGC) where she represented Quebec to the Administrative Committee as Vice-Chair. She was an examiner at the Royal College of Physicians and Surgeons of Canada and has sat on the specialty committees on obstetrics and gynecology since 2006. She has served on the professional inspection committee of the College of Physicians of Quebec from 2006 to 2012. Dr. Francoeur served as a medical expert to establish the Advisory Committee for the College of Midwives of Quebec. Also since 2006 she has served on the national mother-to-child MSSS table. She was a guest speaker at numerous scientific conferences to address the pediatric and adolescent gynecology and hemostasis and thrombosis problems of women. Dr. Francoeur is also very involved in the organization of health care and management of the conduct of medical specialists.

Dr. Robert Halpenny received his BSc (Physical Education) from the University of Guelph and then played professional hockey in Vienna, Austria, and Winston-Salem, North Carolina. He received his Medical Degree from the University of Saskatchewan, completing his Family Practice Residency from the University of British Columbia before starting private practice in Vancouver. Dr. Halpenny was Vice-President of Medicine at St. Vincent’s Hospital in Vancouver, where he participated in the merger of five Catholic hospitals. In pursuing his interest in health care administration, Dr. Halpenny completed a Master of Science in Health Administration from the University of Colorado in 1995. He was Vice-President of Medicine at St. Mary’s Hospital in Grand Junction, Colorado, where he accomplished a joint venture between investing physicians and the hospital to build and operate an Ambulatory Surgery Center. Returning to Canada in 2002 as the Vice-President of Medical Affairs for the Fraser Health Authority, he then became the Provincial Executive Director of Cardiac Services for British Columbia (BC). Dr. Halpenny has also been the Senior Medical Director of Interior Health based out of Kelowna and, in January 2010, became its President and CEO. Dr. Halpenny sits on the BC Medical Services Commission, the BC Emergency and Health Services Commission, and on the Management Board of Health Shared Services BC.


15 | Page

Mike Tierney is Vice President of Clinical Programs at The Ottawa Hospital and his portfolio includes Emergency, Critical Care, Medicine, Neurosciences and Geriatrics. He has over 30 years of experience in healthcare, including past roles as Director of Pharmacy at The Ottawa Hospital and Vice President of the Common Drug Review at the Canadian Agency for Drugs and Technologies in Health (CADTH). Career experiences include clinical pharmacy practice in adult critical care, clinical education and research and the application of an evidence-informed approach to healthcare decision making. MODERATOR: Thomas William Noseworthy CM MD MSc MPH, FRCPC, FACP, FCCP, FCCM, CHE, is Professor of Health Policy and Management, Department of Community Health Sciences and Institute for Public Health, University of Calgary. He is the former Head of that Department and inaugural Co-Director of that Institute. Dr. Noseworthy is a physician, with specialty certification in the Royal College of Physicians and Surgeons of Canada, the American College of Physicians, American College of Chest Physicians, and the American College of Critical Care Medicine. Dr Noseworthy is the former Vice-President, Medical Services, and CEO of the Royal Alexandra Hospital, Edmonton; and Chair of the Department of Public Health Sciences, Faculty of Medicine & Dentistry, University of Alberta. He holds a Master of Science in Experimental Medicine from the University of Alberta, and a Master of Public Health - Health Policy and Management from Harvard University. Dr. Noseworthy has been a member of the National Statistics Council since 1999. He served as a member of the Prime Minister’s National Forum on Health from 1994 to 1997, and chaired the Steering Committee; co-chaired the Advisory Council on Health Infostructure from 1997 to 1999; chaired the Senior Reference Committee for Alberta Wellnet from 1997 to 2002; and was Chair of the Western Canada Waiting List Project from 1999 to 2006, and now chairs the research collaboration known as the Western Canada Waiting List Investigators, a CIHR-funded Emerging Team. His research has been published in over 100 papers and book chapters, and focuses on health care access and improving quality management of waiting times for scheduled services. He was a founding Director of Canadian Doctors for Medicare in 2007.


16 | Page

PLENARY 3

April 8, 2014 1500 – 1615

Rethinking the QALY Health care funders expect value for money for every dollar invested. One of the tools used to assess the value for money of a medical intervention is the QALY or quality-adjusted life-year — a measure of health gain that also considers both the quality and the quantity of life lived. How effective has the QALY been in providing information relevant to decision-makers? Are other values that are important to decision-makers, patients, and the public adequately represented by the QALY? Are there other approaches we should consider that would help us get a better handle on values? Dr. Jennifer Gibson is Interim Director of the University of Toronto Joint Centre for Bioethics (JCB) and Associate Professor in the Institute of Health Policy, Management, and Evaluation at the University of Toronto. Jennifer holds a PhD in philosophy, with a specialization in bioethics, from the University of Toronto. Her current funded research focuses on ethics and health system integration, organizational ethics, social media and cancer control policy, and interdisciplinary approaches to resource allocation in health institutions. Jennifer leads the World Health Organization (WHO) Collaborating Centre for Bioethics at the University of Toronto, is a program team leader for Societal Values and Public Engagement at the Canadian Centre for Applied Research in Cancer Control, and serves on the advisory boards of various government and professional organizations. Ansgar Hebborn, PhD is Roche Pharma’s Head of Global Market Access Policy based in Basel, Switzerland. In this role Ansgar is responsible for the development of Roche’s external policy positions and projects on market access subjects including Health Technology Assessment (HTA) and pricing. Ansgar is a member and active contributor to national and international pharmaceutical policy forums as well as professional associations. He currently represents Roche in relevant industry associations such as in the European Federation of Pharmaceutical Industries and Associations (EFPIA) as a member of the Economic and Social Policy Committee (ESPC) and the HTA Working Group. During the past couple of years, Ansgar has taken an active role as advisor and stakeholder representative in various HTA collaboration networks such as the EUnetHTA and the Health Technology Assessment International (HTAi) Policy Forum, and also has been involved in the foundation of other initiatives in this field, such as the Green Park Collaborative and SwissHTA. He has also been a member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Board of Directors.


17 | Page

Don Husereau is a Senior Associate with the Institute of Health Economics. He is also an Adjunct Professor of Medicine at The University of Ottawa and a Senior Scientist at the University for Health Sciences, Medical Informatics and Technology in Tyrol, Austria. He served as a Director and Senior Advisor for the Canadian Agency for Drugs and Technologies in Health (CADTH) and was a past Director for the International Society of Pharmacoeconomics and Outcomes Research (ISPOR). After joining CADTH in 2001 he led the development of several programs including an environmental scanning program, a rapid review service, a network of Canadian Health Technology Assessment (HTA) producers, and a coordinated national process for the identification, refinement, prioritization, and assignment of HTA. Don received both his BSc in Pharmacy (1993) and his MSc (2000) from the University of Alberta's faculty of Pharmacy and Pharmaceutical Sciences. Professor Christopher McCabe is a health economist and Principal Investigator on PACEOMICS. His primary research interest is in the development of efficient research and development processes for biotherapies and devices in the context of value-based reimbursement market access hurdles. He has published more than 100 peer-reviewed papers, book chapters, and monographs. He holds a Capital Health Endowed Research Chair at the University of Alberta, having previously held Chairs at the Universities of Leeds, Warwick, and Sheffield. He continues to hold a Visiting Chair at the University of Leeds. He has acted as a consultant for public and private sector organizations in Europe, North America, and Australasia; most notably with the National Institute for Health and Care Excellence (NICE) in the United Kingdom, with which he held various roles between 2003 and 2011.

MODERATOR: Dr. Stirling Bryan is Director of the Centre for Clinical Epidemiology & Evaluation, and Professor in the School of Population and Public Health at the University of British Columbia. He is also honorary professor at the University of Birmingham (UK) and an adjunct associate at the Center for Health Policy at Stanford University. In 2005-2006, Dr. Bryan was a Commonwealth Fund Harkness Fellow in Health Care Policy, based at Stanford. He sits on the editorial board of Health Economics, a journal for which he is also an associate editor. Dr. Bryan's research interests span the areas of outcome measurement, economic evaluation, health technology assessment, and health care decision-making. His work includes both applied and methodological contributions.

The Canadian Foundation for Healthcare Improvement is a not-for-profit organization funded through an agreement with the Government of Canada.

Innovations at the Winnipeg Regional Health Authority…

shouldn’t just stay at the WRHA.Right now there’s an innovative way to reduce antipsychotic medication use in long term care patients with dementia.Want to learn how we can help your organization implement these promising practices?

Let’s talk funding and support at:cfhi-fcass.ca/innovation.

www.ihe.caAn independent, Alberta-based not-for-profit

health research organization.We conduct commissioned projects/programs for a variety of public and private funders in:• HTA, health economics, and decision analytic modeling• Health services and health policy research• Evidence-informed guidance development, through the

Alberta Ambassador Program• Knowledge transfer, policy roundtables, scientific

meetings, and consensus development conferences

IHE operates as the host for Secretariats for both HTA International

www.htai.organd the International Network

of Agencies for HTA www.inahta.org

U PCOM I NG EVE NT - R EG ISTE R NOW:Canadian Consensus Development Conference on Surveillance and Screening for AROs (Anti-Microbial-Resistant Organisms)

June 18-20, 2014 • www.AROsCalgary2014.ca

HTAi is the global scientific and professional society for all those who produce, use, or encounter HTA. HTAi embraces all stakeholders, including researchers, agencies, policymakers, industry, academia, health service providers, and patients/consumers, and acts as a neutral forum for collaboration and the sharing of information and expertise. With members from 59 countries and six continents, HTAi is a thriving global network.

HTAi is actively committed to international collaboration, and has signed formal Memoranda of Understanding with the World Health Organization and the International Network of Agencies for HTA (INAHTA). From time to time, HTAi takes part in external initiatives in collaboration with other organizations. The Board of Directors may designate members to represent the society on external initiatives, and interested members encouraged to contact the HTAi Secretariat.

Health Technology Assessment internationalAn International Society for the Promotion of Health Technology Assessment

Optimizing Patient-Centered Care in an era of Economic Uncertainty

June 15-18, 2014Grand Hyatt WashingtonWashington DC, USA

Guest Speaker: Patrick Conway

Please come join us at our Annual Conference in Washington D.C. where you can meet with leaders of HTA agencies from around the world.

Early Registration Deadline: April 8, 2014

www.HTAi2014.org

Join Canadian and International experts in the production and use of

evidence-based information on health technologies, in Saskatoon, for three days of education and networking.

MARK YOUR CALENDAR NOW:

2015 CADTH SymposiumApril 12 – 14, 2015

Saskatoon, Saskatchewan

Watch cadth.ca/symposium2015 formore information or contact us byemail at [email protected].

the realities of health care decision-making · welcome to the 2014 cadth symposium, the tenth...

Documents